litlas
Log inCreate account

Malcolm J. Moore

Active 1987–2025

113
Papers
54,563
Citations
90
h-index
112
i10-index

Citations

Citations per year for Malcolm J. Moore1987: 1 citations1988: 5 citations1989: 2 citations1990: 2 citations1991: 5 citations1992: 2 citations1993: 3 citations1994: 5 citations1995: 13 citations1996: 16 citations1997: 30 citations1998: 26 citations1999: 73 citations2000: 92 citations2001: 92 citations2002: 149 citations2003: 132 citations2004: 168 citations2005: 214 citations2006: 233 citations2007: 261 citations2008: 277 citations2009: 374 citations2010: 443 citations2011: 391 citations2012: 449 citations2013: 436 citations2014: 444 citations2015: 503 citations2016: 459 citations2017: 457 citations2018: 421 citations2019: 1,449 citations2020: 1,471 citations2021: 1,296 citations2022: 838 citations2023: 611 citations2024: 954 citations2025: 386 citations2026: 14 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 4,456 citing papers, 27.6% of this breakdownChina: 1,334 citing papers, 8.3% of this breakdownGermany: 991 citing papers, 6.2% of this breakdownUnited Kingdom: 956 citing papers, 5.9% of this breakdownItaly: 917 citing papers, 5.7% of this breakdownJapan: 808 citing papers, 5% of this breakdownCanada: 803 citing papers, 5% of this breakdownFrance: 712 citing papers, 4.4% of this breakdownNetherlands: 518 citing papers, 3.2% of this breakdownSpain: 507 citing papers, 3.1% of this breakdownAustralia: 416 citing papers, 2.6% of this breakdownSouth Korea: 333 citing papers, 2.1% of this breakdown
0%27.6%Other 20.9%

Institutions

Fields

  • Medicine73.8%
  • Biochemistry, Genetics and Molecular Biology18%
  • Immunology and Microbiology2%
  • Materials Science1.3%
  • Computer Science0.8%
  • Engineering0.7%
  • Other3.4%

Topics

  • Pancreatic and Hepatic Oncology Research11.1%
  • Colorectal Cancer Treatments and Studies5%
  • Cancer Genomics and Diagnostics3.9%
  • Cholangiocarcinoma and Gallbladder Cancer Studies2.8%
  • Cancer Immunotherapy and Biomarkers2.2%
  • Cancer Cells and Metastasis1.9%
  • Other73.1%

Coauthors

All papers

Open in search
  1. Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

    Authors: Daniel D. Von Hoff, Thomas J. Ervin, Francis P. Arena, E. Gabriela Chiorean, Jeffrey R. Infante, Malcolm J. Moore, Thomas E. Seay, Sergei Tjulandin, Wen Wee, Mansoor N. Saleh, Marion Harris, Michele Reni, Scot Dowden, Daniel A. Laheru, Nathan Bahary, Ramesh K. Ramanathan, Josep Tabernero, Manuel Hidalgo, David Goldstein, Eric Van Cutsem, Xinyu Wei, José Iglesias, Markus F. Renschler - New England Journal of Medicine 2013 cited by 6,661

  2. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.

    Authors: Howard A. Burris, Malcolm J. Moore, John Sahl Andersen, M R Green, Mace L. Rothenberg, Manuel Modiano, M. Christine Cripps, Russell K. Portenoy, Anna Maria Storniolo, Peter G. Tarassoff, Ryan Nelson, F. Andrew Dorr, Connie Stephens, Daniel D. Von Hoff - Journal of Clinical Oncology 1997 cited by 5,884

  3. Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group

    Authors: Malcolm J. Moore, David Goldstein, John Hamm, Arié Figer, J. Randolph Hecht, Steven Gallinger, H. Au, P. Murawa, David Walde, Robert A. Wolff, Daniel de Castro, Robert Lim, Keyue Ding, Gary M. Clark, Theodora Voskoglou-Nomikos, Mieke Ptasynski, Wendy R. Parulekar - Journal of Clinical Oncology 2007 cited by 3,859

  4. Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial

    Authors: Kyaw Aung, Sandra E. Fischer, Robert E. Denroche, Gun-Ho Jang, Anna Dodd, Sean Creighton, Bernadette Southwood, Sheng‐Ben Liang, Dianne Chadwick, Amy Zhang, Grainne M. O’Kane, Hamzeh Albaba, Shari Moura, Robert C. Grant, Jessica K. Miller, Faridah Mbabaali, Danielle Pasternack, Ilinca M. Lungu, John M.S. Bartlett, Sangeet Ghai, Mathieu Lemire, Spring Holter, Ashton A. Connor, Richard A. Moffitt, Jen Jen Yeh, Lee E. Timms, Paul M. Krzyzanowski, Neesha C. Dhani, David W. Hedley, Faiyaz Notta, Julie M. Wilson, Malcolm J. Moore, Steven Gallinger, Jennifer J. Knox - Clinical Cancer Research 2017 cited by 636

  5. Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial

    Authors: Camilla Zimmermann, Nadia Swami, Monika K. Krzyzanowska, Breffni Hannon, Natasha B. Leighl, Amit M. Oza, Malcolm J. Moore, Anne Rydall, Gary Rodin, Ian F. Tannock, Allan Donner, Christopher Lo - The Lancet 2014 cited by 1,796

  6. K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer

    Authors: Christos S. Karapetis, Shirin Khambata‐Ford, Derek J. Jonker, Chris J. O’Callaghan, Dongsheng Tu, Niall C. Tebbutt, R. J. Simes, Haji Chalchal, Jeremy Shapiro, Sonia Robitaille, Timothy Price, Lois E. Shepherd, Heather‐Jane Au, Christiane Langer, Malcolm J. Moore, John Zalcberg - New England Journal of Medicine 2008 cited by 3,597

  7. Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study

    Authors: Hans von der Maase, Steen Werner Hansen, J.T. Roberts, Luigi Dogliotti, T. Oliver, Malcolm J. Moore, I. Bodrogi, Peter Albers, Alexander Knuth, Christian Lippert, Pierre Kerbrat, Pedro Sánchez‐Rovira, Peter Wersäll, Simon Cleall, D. Roychowdhury, Irene Tomlin, Carla Visseren‐Grul, PierFranco Conte - Journal of Clinical Oncology 2000 cited by 2,286

  8. Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection

    Authors: John P. Neoptolemos, Deborah Stocken, Claudio Bassi, Paula Ghaneh, David Cunningham, David Goldstein, Robert Padbury, Malcolm J. Moore, Steven Gallinger, C. Mariette, Moritz N. Wente, Jakob R. Izbicki, Helmut Friess, Markus M. Lerch, Christos Dervenis, Attila Oláh, Giovanni Butturini, Ryuichiro Doi, Pehr Lind, David B. Smith, Juan W. Valle, Daniel H. Palmer, John Buckels, Joyce Thompson, Colin J. McKay, Charlotte Rawcliffe, Markus W. Büchler, for the European Study Group for Pancreatic Cancer - JAMA 2010 cited by 1,387

  9. Adjuvant nab -Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial

    Authors: Margaret A. Tempero, Uwe Pelzer, Eileen M. O’Reilly, Jordan M. Winter, Do‐Youn Oh, Chung‐Pin Li, Giampaolo Tortora, Heung-Moon Chang, Charles D. Lopez, Tanios Bekaii‐Saab, Andrew H. Ko, Armando Santoro, Joon Oh Park, Marcus Smith Noel, Giovanni Luca Frassineti, Yan‐Shen Shan, Andrew Dean, Hanno Riess, Eric Van Cutsem, Jordan Berlin, Philip Philip, Malcolm J. Moore, David Goldstein, Josep Tabernero, Mingyu Li, Stefano Ferrara, Yvan Le Bruchec, George Zhang, Brian Lu, Andrew V. Biankin, Michele Reni, Richard A. Epstein, Paul L. Vasey, Jeremy Shapiro, Matthew Burge, Yu Jo Chua, Marion Harris, Nick Pavlakis, Niall C. Tebbutt, Gerald W. Prager, Christian Dittrich, Friedrich Längle, Kathrin Philipp‐Abbrederis, Richard Greil, Herbert Stöger, Michael Girschikofsky, Thomas Kuehr, Jean–Luc Van Laethem, Stéphanie Laurent, Neesha C. Dhani, Yoo Joung Ko, Scot Dowden, Petr Kavan, Mustapha Édouard Tehfe, Eugen Kubala, Milan Kohoutek, Per Pfeiffer, Mette Yilmaz, Vibeke K. Parner, Tapio Salminen, Leena‐Maija Soveri, Eija Korkeila, Pia Österlund, Julien Taı̈eb, David Tougeron, Pascal Artru, François‐Xavier Caroli‐Bosc, Rosine Guimbaud, Antony Turpin, Thomas Walter, Jean‐Baptiste Bachet, Volker Kunzmann, Florian Kreth, Andreas De Block, Marino Venerito, Helmut Oettle, Meinolf Karthaus, Jörg Trojan, Gunnar Folprecht, Markus M. Lerch, Frank Kullmann, Marcel Reiser, Volker Heinemann, Marcus‐Alexander Wörns, H. Schulz, Benjamin Garlipp, Thomas Yau, Lam Stephen Chan, Balázs Juhász, László Landherr, Tamás Pintér, G. Bodoky, Zsuzsanna Kahán, Raymond McDermott, Derek G. Power, Luca Gianni, Salvatore Siena, Michèle Milella, Alfredo Falcone, Rossana Berardi and 87 more - Journal of Clinical Oncology 2022 cited by 132

  10. Cetuximab for the Treatment of Colorectal Cancer

    Authors: Derek J. Jonker, Chris J. O’Callaghan, Christos S. Karapetis, John Zalcberg, Dongsheng Tu, Heather-Jane Au, Scott Berry, Marianne Krahn, Timothy Price, R. J. Simes, Niall C. Tebbutt, Guy van Hazel, Rafal Wierzbicki, Christiane Langer, Malcolm J. Moore - New England Journal of Medicine 2007 cited by 1,806

  11. Evaluating the Time Toxicity of Cancer Treatment in the CCTG CO.17 Trial

    Authors: Arjun Gupta, Christopher J. O’Callaghan, Liting Zhu, Derek J. Jonker, Ralph Wong, Bruce Colwell, Malcolm J. Moore, Christos S. Karapetis, Niall C. Tebbutt, Jeremy Shapiro, Dongsheng Tu, Christopher M. Booth - JCO Oncology Practice 2023 cited by 69

  12. Altered Gene Expression along the Glycolysis–Cholesterol Synthesis Axis Is Associated with Outcome in Pancreatic Cancer

    Authors: Joanna M. Karasinska, James T. Topham, Steve E. Kalloger, Gun Ho Jang, Robert E. Denroche, Luka Culibrk, Laura M. Williamson, Hui‐Li Wong, Michael K.C. Lee, Grainne M. O’Kane, Richard A. Moore, Andrew J. Mungall, Malcolm J. Moore, Cassia Warren, Andrew Metcalfe, Faiyaz Notta, Jennifer J. Knox, Steven Gallinger, Janessa Laskin, Marco A. Marra, Steven J.M. Jones, Daniel J. Renouf, David F. Schaeffer - Clinical Cancer Research 2019 cited by 232

  13. Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer

    Authors: Leonard B. Saltz, John V. Cox, Charles D. Blanke, Lee S. Rosen, Louis Fehrenbacher, Malcolm J. Moore, Jean A. Maroun, Stephen P. Ackland, Paula K. Locker, Nicoletta Pirotta, Gary Elfring, Langdon L. Miller - New England Journal of Medicine 2000 cited by 3,010

  14. Effect of Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid or Gemcitabine vs Observation on Survival in Patients With Resected Periampullary Adenocarcinoma

    Authors: John P. Neoptolemos, Malcolm J. Moore, Trevor F. Cox, Juan W. Valle, Daniel H. Palmer, Alexander C. McDonald, Ross Carter, Niall C. Tebbutt, Christos Dervenis, David Smith, Bengt Glimelius, Richard Charnley, F Lacaine, Andrew Scarfe, Mark R. Middleton, Alan Anthoney, Paula Ghaneh, Christopher Halloran, Markus M. Lerch, Attila Oláh, Charlotte Rawcliffe, Caroline S. Verbeke, Fiona Campbell, Markus W. Büchler, for the European Study Group for Pancreatic Cancer - JAMA 2012 cited by 592

  15. Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers

    Authors: Talia Golan, Zaheer Kanji, Ron Epelbaum, Nicholas Devaud, Efrat Dagan, Spring Holter, Dan Aderka, Shani Paluch–Shimon, Brett A. Kaufman, Ruth Gershoni‐Baruch, David W. Hedley, Malcolm J. Moore, Eitan Friedman, Steven Gallinger - British Journal of Cancer 2014 cited by 438

  16. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial

    Authors: Aimery de Gramont, Eric Van Cutsem, Hans‐Joachim Schmoll, Josep Tabernero, Stephen Clarke, Malcolm J. Moore, David Cunningham, Thomas H. Cartwright, J. Randolph Hecht, Fernando Rivera, Seock‐Ah Im, G. Bodoky, Ramón Salazar, Frédérique Maindrault-Goebel, Einat Shacham‐Shmueli, Emilio Bajetta, Martina Makrutzki, Aijing Shang, Thierry André, Paulo M. Hoff - The Lancet Oncology 2012 cited by 526

  17. NRG1 Gene Fusions Are Recurrent, Clinically Actionable Gene Rearrangements in KRAS Wild-Type Pancreatic Ductal Adenocarcinoma

    Authors: Martin Jones, Laura Williamson, James T. Topham, Michael K.C. Lee, Angela Goytain, Julie Ho, Robert E. Denroche, Gun-Ho Jang, Erin Pleasance, Yaoquing Shen, Joanna M. Karasinska, John Paul McGhie, Sharlene Gill, Howard J. Lim, Malcolm J. Moore, Hui‐Li Wong, Tony Ng, Stephen Yip, Wei Zhang, Sara Sadeghi, Carolyn Reisle, Andrew J. Mungall, Karen Mungall, Richard A. Moore, Yussanne Ma, Jennifer J. Knox, Steven Gallinger, Janessa Laskin, Marco A. Marra, David F. Schaeffer, Steven J.M. Jones, Daniel J. Renouf - Clinical Cancer Research 2019 cited by 159

  18. A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial

    Authors: Charles S. Fuchs, Sérgio Jobim Azevedo, Takuji Okusaka, Jean‐Luc Van Laethem, Lara Lipton, Hanno Riess, Cezary Szczylik, Malcolm J. Moore, Marc Peeters, G. Bodoky, Masafumi Ikeda, Bohuslav Melichar, Radim Němeček, S. Ohkawa, Anna Świeboda-Sadlej, Sergei Tjulandin, Eric Van Cutsem, Robert D. Loberg, Vincent Haddad, Jennifer Gansert, Bruce Allen Bach, Alfredo Carrato - Annals of Oncology 2015 cited by 164

  19. Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic Cancer

    Authors: Eric Van Cutsem, Walter L. Vervenne, Jaafar Bennouna, Yves Humblet, Sharlene Gill, Jean‐Luc Van Laethem, Chris Verslype, Werner Scheithauer, Aijing Shang, Jan Cosaert, Malcolm J. Moore - Journal of Clinical Oncology 2009 cited by 643

  20. PANCREOX: A Randomized Phase III Study of Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy

    Authors: Sharlene Gill, Yoo‐Joung Ko, C. Cripps, Annie Beaudoin, Sukhbinder Dhesy‐Thind, Muhammad Zulfiqar, Paweł Zalewski, Thuan Do, Pablo Cano, Wendy Yin Han Lam, Scot Dowden, Helene Grassin, John A. Stewart, Malcolm J. Moore - Journal of Clinical Oncology 2016 cited by 291

  21. DNA Mismatch Repair Status and Colon Cancer Recurrence and Survival in Clinical Trials of 5-Fluorouracil-Based Adjuvant Therapy

    Authors: Frank A. Sinicrope, Nathan R. Foster, Stephen N. Thibodeau, Silvia Marsoni, G Monges, Roberto Labianca, Greg Yothers, Carmen J. Allegra, Malcolm J. Moore, Steven Gallinger, Daniel J. Sargent - JNCI Journal of the National Cancer Institute 2011 cited by 529

  22. Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma

    Authors: Spring Holter, Ayelet Borgida, Anna Dodd, Robert C. Grant, Kara Semotiuk, David W. Hedley, Neesha C. Dhani, Steven A. Narod, Mohammad R. Akbari, Malcolm J. Moore, Steven Gallinger - Journal of Clinical Oncology 2015 cited by 396

  23. Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17

    Authors: Stephanie Yasmin Brule, Derek J. Jonker, Christos S. Karapetis, Chris J. O’Callaghan, Malcolm J. Moore, Ralph Wong, Niall C. Tebbutt, Craig Underhill, Desmond Yip, John Zalcberg, Dongsheng Tu, Rachel Goodwin - European Journal of Cancer 2015 cited by 337

  24. Advanced pancreatic carcinoma: current treatment and future challenges

    Authors: Anastasios Stathis, Malcolm J. Moore - Nature Reviews Clinical Oncology 2010 cited by 791